Headline
The latest stories from AHA Today.
In a new report, the AHA estimates that the financial impact to hospitals and health systems from COVID-19 expenses and revenue losses over the four-month period from March 1 and June 30 totals $202.6 billion, with losses averaging over $50 billion per month.
The U.S. Court of Appeals for the 9th Circuit denied the federal government’s request to lift pending appeal a preliminary injunction blocking a presidential proclamation requiring most individuals seeking to enter the United States via an immigrant visa to have approved health insurance coverage…
The national generosity movement known as Giving Tuesday has designated May 5 as #GivingTuesdayNow, a global day of giving in response to the unprecedented need caused by COVID-19.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is enrolling 2,000 U.S. families in a study to help determine the COVID-19 infection rate in U.S. children and their family members, and the share of infected children who develop symptoms.
The Department of Homeland Security and the Cybersecurity and Infrastructure Security Agency have updated their telework guidance to include new guidance on telework best practices, videoconferencing tips, guidance for securing videoconferencing, and specific cybersecurity recommendations for…
The Department of Health and Human Services’ Office of Minority Health May 1 announced it will provide funding to help deliver important COVID-19-related information to racial and ethnic minority, rural and socially vulnerable communities hardest hit by the pandemic.
The Centers for Disease Control and Prevention issued preliminary guidance for the development of forthcoming contact tracing apps that can help slow the spread of COVID-19.
The Food and Drug Administration said it is adopting more stringent standards for COVID-19 antibody tests.
The Food and Drug Administration issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
The AHA sent the Health Resources and Services Administration a letter requesting clarifications for several elements of the COVID-19 Uninsured Program.